Guangzhong Guo
Overview
Explore the profile of Guangzhong Guo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
16
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang J, Liu G, Wang D, Bu C, Lv G, Zhang Z, et al.
Neurosurgery
. 2025 Mar;
PMID: 40042315
Background And Objectives: Glioblastoma (GBM) recurrence after surgery remains a significant clinical challenge because of limited early detection methods and effective molecular markers. This study investigates the potential of dynamic...
2.
Guo G, Zhang Z, Zhang J, Wang D, Xu S, Wu S, et al.
Cancer Med
. 2025 Mar;
14(5):e70733.
PMID: 40022576
Background: Glioma recurrence can be divided into in situ recurrence and non-in situ recurrence, and the mutation evolution of gliomas with different recurrence patterns is still unknown. We used sequential...
3.
Wang D, Zhang J, Bu C, Liu G, Guo G, Zhang Z, et al.
J Cancer Res Clin Oncol
. 2024 Oct;
150(10):466.
PMID: 39422764
Purpose: Immune checkpoint blockade (ICB) therapies have shown efficacy in various tumors, but long-term responses in glioblastoma are less than 10%. Quantifying tumor in situ fluid circulating tumor DNA (TISF-ctDNA)...
4.
Guo G, Zhang Z, Zhang J, Wang D, Xu S, Liu G, et al.
Cancer Immunol Immunother
. 2024 Aug;
73(10):193.
PMID: 39105794
Objective: Most recurrent glioblastoma (rGBM) patients do not benefit from immune checkpoint inhibition, emphasizing the necessity for response biomarkers. This study evaluates whether tumor in situ fluid (TISF) circulating tumor...
5.
Sheng Z, Bu C, Mei J, Xu S, Zhang Z, Guo G, et al.
Front Oncol
. 2023 Nov;
13:1238607.
PMID: 37920153
Objective: Tumor fluid (TISF) refers to the fluid within surgical cavities of glioma. Several studies preliminarily proved the value of cell-free tumor DNA (cf-tDNA) from TISF in the dynamic characterization...
6.
Liu G, Bu C, Guo G, Zhang Z, Sheng Z, Deng K, et al.
iScience
. 2023 Aug;
26(9):107528.
PMID: 37649695
The evolutionary trajectories of genomic alterations underlying distant recurrence in glioma remain largely unknown. To elucidate glioma evolution, we analyzed the evolutionary trajectories of matched pairs of primary tumors and...
7.
Liu G, Bu C, Guo G, Zhang Z, Sheng Z, Deng K, et al.
Cancer Med
. 2023 Aug;
12(16):17171-17183.
PMID: 37533228
Background: Oligodendroglioma is known for its relatively better prognosis and responsiveness to radiotherapy and chemotherapy. However, little is known about the evolution of genetic changes as oligodendroglioma progresses. Methods: In...
8.
Xu S, Sheng Z, Yu J, Deng K, Wu S, Bu Y, et al.
Clin Transl Med
. 2022 Jul;
12(7):e956.
PMID: 35802830
No abstract available.